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Abstract
Our understanding of the link between the human microbiome and disease, including obesity, 
inflammatory bowel disease, arthritis and autism, is rapidly expanding. Improvements in the 
throughput and accuracy of DNA sequencing of the genomes of microbial communities associated 
with human samples, complemented by analysis of transcriptomes, proteomes, metabolomes and 
immunomes, and mechanistic experiments in model systems, have vastly improved our ability to 
understand the structure and function of the microbiome in both diseased and healthy states. 
However, many challenges remain. In this Review, we focus on studies in humans to describe 
these challenges, and propose strategies that leverage existing knowledge to move rapidly from 
correlation to causation, and ultimately to translation.
Introduction
The microbial cells that colonize the human body, including in mucosal and skin 
environments, are at least as abundant as our somatic cells1, and certainly contain far more 
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genes than our human genome (Box 1). An estimated 500–1000 species of bacteria exist in 
the human body at any one time2, although the number of unique genotypes (sub-species) 
could be orders of magnitude greater than this3. Each bacterial strain has a genome 
containing thousands of genes, offering substantially more genetic diversity and hence 
flexibility than the human genome. However, different people harbour radically different 
collections of microbes with substantially varying densities even among conserved taxa, and 
we understand little about what leads to and what regulates this variation. Importantly, we do 
not yet understand how the variation within a person over time, or between different people, 
influences wellness, the preservation of health, or the onset and progression of disease. 
However, we do know that changes in the microbiome, and microbial metabolome and their 
interaction with the immune, endocrine, and nervous system are correlated with a wide array 
of illnesses, ranging from inflammatory bowel disease 4–6 to cancer7 to major depressive 
disorder 8,9.
Human microbiome investigations have now reached a critical inflection point. We are 
transitioning from description and investigation to understanding mechanism, and 
developing novel clinical interventions based on this understanding10. These advances have 
also created a surge in translational research, resulting in substantial private investment not 
only in academic research, but also in the private sector, including so-called “Big Pharma”. 
This drive toward clinical microbiome studies is supported by a revolution in personalized 
medicine, in which, for example, the decline in cost of cancer genome sequencing is 
allowing the rapid identification of the precise treatment regimen that will lead to a positive 
outcome in an individual patient, for example, with colorectal cancer11. Our ability to 
rapidly and reproducibly characterize the microbiome, like cancer genomics, offers an 
opportunity to develop fundamentally new diagnostic biomarkers and therapeutics.
Here we present the current state of knowledge linking the microbiome to human disease. 
We have focused on human studies when possible, but also highlight select mouse studies 
when human studies are not available. This is to provide a platform from which to explore 
the future of applied clinical microbiome research.
We will strategize on how to progress from the correlative and biomarker studies towards 
studies that will reveal the underlying mechanisms and opportunities for new preventive and 
therapeutic modalities.
Factors influencing the human microbiome
To alter the microbiome deliberately for preventive or therapeutic purposes, or use it to 
understand a particular medical condition, we must first understand the factors that influence 
its composition. We have reviewed many of these factors in detail recently10,12, so we 
provide only a brief summary here.
Human genetics and immune interactions in early development
The composition of the human microbiome is unique in each individual, and the differences 
among individuals are large compared to the typical biochemical differences within a person 
over time13,14. Identical twins are barely more similar to one another in microbial 
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composition and structure than are non-identical twins15, at least over the range of 
environmental factors captured in studies to date, suggesting that the effect of the human 
genome is limited, and that most of microbial community assembly may be determined by 
environmental factors. Early underpowered studies suggested that monozygotic twins were 
no more similar in terms of their overall gut microbiota than dizygotic twins16–18, although 
larger cohort sizes show a small but statistically significant effect of genetics on microbiome 
composition in twins with certain taxa being identified as highly heritable, such as 
Christensenella15. However, one way to rationalize this is that the number of bacteria that 
are able to successfully colonize humans is limited. Colonizing initially germ-free mice with 
diverse environmental samples demonstrates that very few bacteria present in the 
environment can survive in the mouse gut, and those that do are rapidly displaced by human- 
or mouse-derived bacteria on exposure19 Furthermore, human immune responses shape 
responses to changes in the microbiome and are involved in shaping the microbiome itself20.
Most human immunological studies regrettably still lack a microbiome component, that will 
be essential to untangling the relationship between the immune response and microbial 
colonisation and stability. The mammalian immune system has a complex and dynamic 
bidirectional relationship with the microbiome. Although, recent human cohort studies 
suggest that most of the variability in human immune response to stimulation derives from 
the genome, at least 10% of this immune response variability derives directly from 
interactions associated with the microbiome21.
The large majority of microbiome colonization occurs in the early years of life. This topic 
has been reviewed extensively22,23. During and shortly after birth, newborns are exposed to 
maternal and environmental microbes initiating gut microbiome establishment24. Within the 
first year of life, an estimated 1013 to 1014 microbes/ml comprising 500–1000 species 
colonize the gastrointestinal tract25. After weaning, the gut microbiota becomes firmly 
established, leading to a lifelong microbiome signature in healthy individuals26.
Body site
When the microbiomes of large cohorts of people at a given body site are compared, 
individuals fit on a continuum of microbial diversity within a human population, rather than 
clustering into discrete groups27,28. During human development, the human microbiome 
follows body site-specific trajectories, so that each body site develops a specific 
biogeography (Figure 1). The skin, for example, shows dramatic variation in microbiome 
composition and structure across different sites29. The physical and topographical 
characteristics of skin play a significant role in shaping the microbial community similarity 
between sites30. These factors also play a role in shaping the individuality of the 
microbiome, so that each person develops a unique microbial signature on their skin, 
irrespective of the differences between skin sites31. Similarly, although prolonged physical 
oral interaction between humans influences microbial community composition over time32, 
the oral microbiome still maintains a relatively unique composition in each person33. 
Longitudinal characterization of the human gut microbiome has shown that the adult 
microbiota remain relatively stable and unique to each person, compared to the drastic 
change over the first three years of life31,34.
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However, the microbiome is a living ecosystem, and consequently undergoes fluctuations in 
the growth rate and survival of each of its constituents. For example, changes in diet can 
profoundly impact the gut microbial community structure35,36, and vigorous cleaning can 
temporarily alter the skin microbiome. However, in both cases the original microbiota and 
structure re-emerge when the original conditions resume37. Transit time of food through the 
gut also influences the types of microbes which can proliferate within the gut, with rapid 
transit time selecting for functions associated with biofilm formation or rapid cell 
division38,39. Defining a microbiota based on the relative abundance of its members may 
therefore provide only a limited view of the microbial assemblage, and integrating more 
information about the function of each gene and genome in the context of the ecosystem and 
the host will provide increasingly important insights. Human microbiome variability makes 
blanket stratification difficult for particular disease states, although it is possible to identify 
biomarkers for some conditions [Box 2].
The vaginal microbiome has a similar degree of stability to the skin microbiome, and unlike 
the gut, classifying the vaginal microbiome into discrete states during disease has been 
possible. The vaginal microbiota of asymptomatic women tend to be dominated by 
individual species of Lactobacillus and diverse additional anaerobic taxa40. The Lactobacilli 
are believed to benefit the host by lowering vaginal pH through fermentation end-products, 
thereby reducing the likelihood of allochthonous microbial colonization or pathogen 
invasion. Microbial variation within an individual woman does occur over days to weeks41, 
although menstruation and pregnancy appear to result in a similar microbiome in different 
groups of women42. Diseases such as bacterial vaginosis result in disruption of the ‘normal’ 
vaginal ecosystem function, but also result in a highly similar microbial profile between 
women, thereby providing a generalized biomarker of disease43.
Diet
Diet has been studied extensively in relation to the gut microbiome44, but less so with 
respect to other microbiomes at other sites across the body. Modulating diet is an ideal 
opportunity for low-risk, culturally and psychologically acceptable intervention to change 
the microbiome. Therefore, this avenue of research could yield novel therapeutic strategies 
through targeted dietary interventions should gut microbiota be shown to be causative for 
certain diseases. Evidence to date suggests that long-term diet has very large effects on gut 
microbiome composition45 although a sufficiently extreme short-term dietary change can 
cause people to resemble one another within days35. Fascinatingly, the effects of the same 
dietary ingredient on blood glucose measurements can vary in different people, an effect 
mediated by the microbiome46. Although we know that the microbiome can influence leptin 
concentrations in humans, and hence influence appetite47, an open question is whether the 
microbiome can influence dietary preferences, which could lead to positive feedback loops 
when these dietary changes in turn alter the microbiome.
Antibiotics
The effect of antibiotics on all microbiomes is expected to be large compared to other 
factors, and preliminary studies have been performed to determine the impact48. The gut 
microbiome in adults appears not to be resilient to repeated antibiotic administration49. The 
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same antibiotic appears to affect particular microbes differently depending on the rest of the 
microbiome50, perhaps due to different growth phases, metabolic states, or contextual 
microbial network in which the microorganisms find themselves. An especially interesting 
area of research is the increasing evidence that antibiotics in early life have a profound effect 
of the gut microbiome that can result in the later development of obesity51, asthma, 
inflammatory bowel disease and other disorders.
Lifestyle
Lifestyle is also thought to have a strong influence on microbiome composition. 
Cohabitation with pets, such as dogs, has a statistically significant association with the 
microbiome. In one study, the skin microbiome of couples living together has a closer 
resemblance if the couple has a dog, but, intriguingly, a small child did not provide the same 
trend, so couples with a child but no dog were not significantly more similar to one another 
than couples without a child52. Pet ownership and exposure to livestock have been 
associated with decreased risk of asthma53. Interrupting this exposure in infants from human 
populations with a known ancestral history of interaction with animals has been shown to 
lead to a substantial increase in atopy, especially asthma54. If these results turn out to be 
caused by the microbiome, rather than simply correlative, they suggest potential new 
therapeutic strategies for disease intervention could come from microbial exposure focused 
on immune activation.
Other lifestyle traits have been shown to correlate with the composition of the microbiota. 
For example, exercise appears to influence the structure of the microbiome through reducing 
inflammation, with subtle changes in the microbial community composition correlated with 
changes in cytokine profiles55. Sleep deprivation correlates with changes in the gut 
microbiome, with a greater ratio of Firmicutes to Bacteroidetes and elevated abundance of 
Coriobacteriaceae and Erysipelotrichaceae associated with sleep loss56. Stress increases 
intestinal permeability, and is correlated with changes in Bacteroidetes and Actinobacteria, 
with corresponding shifts in metabolite concentrations and inflammatory markers57.
Occupation has primarily been assumed to influence the microbiome via exposure to 
different environments and place of residence. For example, farmers have a different 
microbiome than city workers58. However, very few microbiome studies have isolated 
occupation as a variable influencing composition. For example, the oral microbiota of sailors 
is significantly altered by their occupational activities, so that after 120 days at sea, they 
show a five-fold reduction in alpha diversity and an increase Streptococcus59. Similarly, 
sexual intercourse in heterosexual couples leads to an increased similarity of the penile and 
vaginal microbiota between sexual partners, which could potentially alter sexual disease 
ecology in the participants; there is emerging evidence that microbiome differences might 
affect transmission of STIs (Sexually Transmitted Infections)60. Finally, couples who 
physically interact have a more similar microbiota than people who share the same living 
quarters but do not physically interact14, indicating that physical interaction influence 
microbial sharing and hence microbiome similarity, highlighting the effects of social 
interaction on the microbiome.
Gilbert et al. Page 5
Nat Med. Author manuscript; available in PMC 2020 February 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Dynamics of the human microbiome
Human interaction with the environment, including with other people, creates the potential 
for specific microbial taxa to either act as an immune-stimulant that influences the 
microbiome through, for example, inflammation, or to act as a source for bacteria, fungi, and 
viruses that can colonize the human body. The identification of bacterial taxa in the gut that 
alter animal hormonal regulation, leading to obesity in mice61, suggests that such events 
may alter our physiology. The composition of the gut microbiome itself is influenced by 
circadian rhythm, and which also then affect host circadian cycles (Figure 2). Disruption of 
the microbial diurnal cycle can lead to disruption in host circadian rhythms, which can 
specifically alter hormone regulation in mice 62. The human microbiome demonstrates 
enormous plasticity, while also being extremely robust on longer timescales and to larger 
types of variation31,34,35, but experiments in mouse models have shown some of the ways in 
which it can be re-shaped.
This apparent dichotomy between dynamism and robustness of the microbiome at first 
glance seems difficult to resolve, until the ecological dynamics of the system are considered. 
All ecosystems undergo variation in species population density and assemblage diversity, but 
with differing magnitudes at different temporal scales. This variation includes competition 
among microbial taxa and shifting metabolic relationships, compounded and influenced by 
the state of the immune system, changing dietary patterns, and a constant exposure to 
bacteria from family and environment. Longitudinal characterization of the host microbiome 
and its sources is therefore essential to capture dynamic variance within an individual, and to 
determine the degree to which the system demonstrates predictable successional traits63.
The plasticity vs. stability dichotomy of the human microbiome is evident over a period of 
days, as was illustrated in the first dense time series analysis of the human microbiome 31 
and confirmed in later ones 34. In that study, two subjects provided daily samples of their 
oral, skin and faecal microbiota, one for six months and the other for fifteen months. The 
results illustrated that at the sequencing depth studied only a tiny fraction of bacterial taxa 
were found to be consistently present across all (or even most) samples in an individual host. 
For the skin sites (the left and right palm) there were no species detected in all samples, 
while in the gut and the mouth, about 5% of the species were defined as belonging to a 
stable temporal core microbiome. Yet each person still maintained a personalized 
microbiome. The degree of personalization of the human microbiome vastly exceeds the 
host genome, which is over 99.5% identical between individuals, suggesting that only 0.5% 
of the genome is unique to an individual. However, based on current observations, two 
individuals can show no overlap in microbial species in their microbiome. This degree of 
personalization is so high that it may even have forensic applications64.
While we are now used to thinking about the composition of the human microbiome being 
personalized, it has also been shown that the rate of change of the human microbiome 
composition is personalized65. In that study, over an approximately three-month period, 85 
college age adults donated weekly microbiome samples from gut, skin, and oral sites. Over 
this timeframe, the microbiome composition remained almost constant in some individuals, 
while that in other individuals abundances changed rapidly. These differing rates of temporal 
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variability were identified at all of the body sites that were profiled (the palm of the 
dominant hand, the forehead, the tongue, and faeces), and the rate of change was not 
correlated across the different sites. On average, skin sites changed most rapidly, followed 
by the gut, and then oral (this pattern matches the relative sizes of the stable temporal core 
microbiome observed in the long-term survey mentioned above31). One potential reason for 
the dynamics in skin is that there are many species at low abundance. None of the 
information collected about the host correlated with the differing rates of change in the 
microbiome, so it was not possible to determine the underlying cause of these differences. 
However, one interesting observation was that individuals who self-reported taking 
antibiotics during (or in the week preceding) the sampling period did not change their 
microbiome composition more rapidly than subjects who did not report taking antibiotics. 
The absence of a difference may reflect that a one-week time frame does not fully capture 
the effects of recent or even lifetime antibiotic use. Nevertheless, on a per individual basis, in 
this study, reported antibiotic usage was typically associated with the largest change in an 
individual’s microbiome overall.
While most studies associate microbiome composition with host disease state, and 
likelihood of response to a treatment, at least one recent study suggests that the rate of 
change of the microbiome may itself be a clinical feature66, as also was observed in a mouse 
model of juvenile diabetes 67. The rate of change of the vaginal microbiome differed across 
women with bacterial vaginosis, and was predictive of the subtype of bacterial vaginosis 
affecting the women. That observation, paired with data indicating that individuals differ in 
the rate of change of their gut, skin, and oral microbiomes, suggests that characterizing 
temporal variability may be an important part of characterizing an individual’s microbiome.
Understanding traits such as variance in microbiome dynamics in individuals, and whether 
that relates to patterns of succession will simplify understanding of causal relationships 
between species and disease, and the interpretation of correlations among taxonomic 
groups68. By prospectively assessing the microbiomes of patients undergoing different 
procedures, we can determine the rate of change, and potentially the rate of recovery of the 
microbiome, if it is altered by the procedure or by the disease state that led to the procedure. 
Doing this in a human population will provide the statistical power to relate these 
measurements to remission of clinical symptoms. Examining the sources that shape the 
microbiome is key to determining this variance.
Bayesian statistics can also be used to map the relative contribution of a specific source to 
the human microbiome over time69, or to create artificial neural networks of conditional 
dependencies that can be used to capture predictive characteristics of a microbial 
network70,71. Using these methods, the dynamic nature of the human microbiome or 
metabolome both within an individual and within a population of individuals can be 
captured. Once gathered, the data can be harnessed to provide a predictive signature or 
characteristic biomarker for a given physiological, immunological or neurological condition. 
The application of machine learning algorithms have also proven to be valuable in 
identifying highly predictive characteristics of a microbial signature to map forensic 
relationships between humans and their built environments14.
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Towards Mechanistic Studies of the Microbiome
Mechanistic studies of the microbiome are typically difficult to perform in humans, in part 
because of tremendous genetic and lifestyle heterogeneity, and there are ethical issues 
associated with colonizing human subjects with microbes that are hypothesized to cause 
disease. Therefore, most of what we know currently stems from experiments in animal 
models. However, recent studies that complement observations in humans with interventions 
in animal models have produced striking new insight into the microbial origins of disease 
that cannot be acquired from human studies alone.
The importance of strain-level resolution for microbiome studies
The field of host-pathogen interactions has long relied on culturing strains of pathogens 
including clinical isolates, and transferring these pathogens to isolated cells, tissues, or 
whole animals to perform intervention studies. Many components of the microbiome have 
been inaccessible to such techniques because the relevant organisms cannot be cultured, 
although recent advances greatly expand the repertoire of the organisms that can be grown 
from the human gut72 so this barrier may be temporary. However, the culturable component 
of the microbiome can still be extraordinarily useful, even if incomplete. For example, a 
recent study in which 53 strains of bacteria were isolated from the human gut and used to 
monocolonize previously germ-free mice revealed large differences in immunomodulatory 
properties of these bacteria, including closely related strains that affected production of 
cytokines such as IL10, IL17a, IL22, and interferon gamma with some promoting and others 
inhibiting production73. These results underscore the need to characterize microbial activity 
at the strain level, not just at the higher taxonomic levels that are typically provided by 
amplicon profiling, and will probably reveal important links between the microbiome and 
disease when extended to more complex communities.
Identifying disease - relevant strains from population studies
Population-based microbiome studies complemented with mechanistic experimental work in 
mice can use microbial associations with phenotype in humans to identify bacteria or 
compounds that then can be tested in intervention studies to reveal causal pathways. For 
example, a study of heritability of different taxa within the gut microbiome in twins in the 
UK revealed that one specific taxon, Christensenella, was highly heritable and associated 
with low BMI in this population15. Strains from this genus were cultured in the lab, and then 
transplanted into germ-free mice, resulting in decreased weight gain in these mice when 
compared to transplantation from an obese human, which would normally induce weight 
gain (as described above).
Similarly, in a comparative study of different human populations in Finland, Russia and 
Estonia, which differ dramatically in the incidence of early-onset autoimmune diseases, 
Bacteroides sp. were especially common in the gut microbiomes of Finnish and Estonian 
children, in whom the incidence of the diseases were lowest, and were hypothesized to 
provide most of the LPS (lipopolysaccharide; a common marker of bacterial infection in the 
bloodstream) exposure in those populations. In contrast, the Russian children had high levels 
of E. coli. in their microbiomes. Tests of the effect injections of LPS from E. coli and B. 
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dorei showed that the former, but not the latter, protected mice with a genetic defect from 
developing autoantibodies and diabetes symptoms, providing a potential explanation for the 
consequences of the different early-life microbiomes on development of autoimmune 
disease in humans74. A similar strategy was used to explain differences in asthma 
development between Amish and Hutterite children in the United States. Dust extracts from 
houses from each population, shown to differ in their microbiome content, were tested in a 
mouse model of asthma development that examines sensitivity to ovalbumin. The tests 
indicated that the dust from Amish but not Hutterite homes protected against asthma 
development54, which was attributed to differences in the bacterial content of the dust. These 
strategies are broadly applicable to many other situations in which differential exposure to 
environmental bacteria may play a role in disease etiology.
Identifying biomarkers in microbiome studies
Some studies are now performing these types of mechanistic experiments in humans 
directly. In one striking example, examining 500 European-ancestry individuals in the 
Netherlands, the authors tested the ability of the individual’s blood to produce cytokines 
after several antigen challenges, then paired these with data about their gut metagenome. 
The data suggest that the yeast Candida albicans had an especially large influence on the 
host’s TNF-alpha response21. This study also associated pathways active in bacteria such as 
palmitoleic acid metabolism with lower systemic inflammatory response; adding palmitoleic 
acid in challenge with C. albicans to an individual’s blood resulted in lower TNF-alpha, but 
unchanged IFN-gamma responses, as predicted from the association data. These types of 
studies are especially useful in conjunction with humans with naturally occurring genetic 
knockouts or variant alleles. These human genetic variants may enable microbially induced 
disease states that can be tested in mice with comparable null or variant genetic changes, as 
has been shown for Parkinson’s Disease.73
Characterizing microbial biomarkers has great potential for precision medicine, and is 
therefore a relatively simple way of translating microbiome research into clinical practice. 
For example, from groundbreaking animal studies, we know that bacterial probiotics (live 
bacteria deliberately introduced to the animal to produce a therapeutic effect) can be used to 
enhance immune checkpoint blockade therapy for melanoma patients75. Studying the 
microbiomes of melanoma patients prior to immune checkpoint blockade therapy has 
identified microorganisms in the gut to be biomarkers for diagnosis that can predict whether 
patients are at risk of developing checkpoint-blockade-induced colitis76.
These prospective studies are extremely important for linking microbial community 
structure, function, and metabolic products to health outcomes. Studies of the microbiome as 
infants develop are also key in this area, and many ongoing investigations, such as the NIH 
Common Core program Environmental Influences on Child Health Outcomes (ECHO: 
https://www.nih.gov/echo), now provide the infrastructure to sequence healthy, susceptible 
and diseased participants to examine how lifestyle and environmental experiences shape the 
development of immune, endocrine and neurological conditions. Although cross-sectional 
single time point studies of birth cohorts provide intriguing statistical associations77, 
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longitudinal prospective studies complemented by mechanistic experiments in animal 
models are required to establish whether a certain microbiome causes disease.
Future studies: developing translational potential
There remains much that we do not understand about the human microbiome. The sources of 
bacteria that colonize an infant include the mother and other caregivers (even one-day-old 
pre-term infants have unique microbiomes that differ from each other and from the mother 
but possibly derived from their mothers78), and human genetics shapes microbiome-immune 
interaction. Given these observations, why do monozygotic twins growing up in the same 
household develop microbiomes that are barely more similar than those of dizygotic twins? 
The role of exogenous immune stimulation in shaping the colonization efficiency of 
different strains must be investigated in more detail. Animal models have produced 
intriguing findings, but prospective longitudinal studies in human infants are required to 
better understand how human genetics influence the developing microbiome. These 
longitudinal investigations will also help us to understand the implication of ecological 
dynamics of the microbiome in health and disease. Microbiome stability (resistance to 
change) and resilience (return to the initial state following perturbation) are essential but 
poorly understood ecological characteristics that can be quantified through longitudinal 
studies by serial collection of DNA sequence data from the microbiome, perhaps 
complemented by metabolite and gene expression profiling. For example, performing 
weekly microbiome profiling of participants before, during and after surgery could help 
identify whether (and which) microbiome ecological dynamics are linked to response to 
surgery, complications, and recovery. Similarly, understanding the resistance and resilience 
of the microbiome to antibiotics requires larger-scale longitudinal studies of diverse cohorts 
(Figure 3). This is especially relevant in childhood, when the microbiome is in flux and may 
be less resistant, but more resilient to these stresses.
As we move forward with transforming microbiome research from a descriptive to causal, 
and finally translational science, the ability to define biomarkers that can stratify patient 
populations within a disease state represents ‘low-hanging fruit’ (Box 2). Of course, the 
effort required to take advantage of these biomarkers is considerable. Clinical studies that 
recruit large and representative patient populations to examine the response to a new drug or 
therapeutic intervention should definitely consider the opportunity to collect data on both 
immune function and the microbiome. These additional variables may lead to new non-
invasive diagnostic platforms. In the future, it may be possible to request a stool or vaginal 
sample, or even an saliva sample (which has been shown to yield effective microbial 
biomarkers for diseases not centered on the mouth such as rheumatoid arthritis79 (Box 2)) 
from a patient prior to a surgical intervention. Then, along with their genome and medical 
history, scientists could make a more accurate prediction about the likelihood of successful 
outcome and/or of complications for each proposed intervention. This additional 
information, if presented in a sufficiently clear format, would substantially aid clinicians by 
providing new data layers that enrich the decision-making process. To realize this vision, we 
must better understand the factors that influence the microbiome of a healthy individual, and 
how the microbiome is reshaped during different health and disease states.
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Concluding Remarks
Microbiome analysis, and so-called Microbiome Wide Association Studies (MWAS)10, are 
revolutionizing clinical investigations by providing greater patient stratification and new 
biomarkers of disease. We are poised to make great advances in patient care over the next 
decade as we improve our ability to characterize and manipulate the microbiome and its 
metabolism. The omics tools available to perform this characterization have been developed 
independently, but now there is an ongoing concerted effort80,81 to better standardize and 
integrate methods and data resources to improve our ability to understand microbial 
dynamics in human systems. Systems microbiome medicine approaches are rapidly finding 
their way into clinical investigations, and this is producing a need to integrate traditional 
clinical statistics and epidemiology with microbial ecological statistics and theory. While 
these two concepts are not mutually exclusive, they are often treated as such; a new breed of 
data scientist is required as early-career clinician-scientists develop their new skills in this 
rapidly expanding field. This in turn increases the likelihood that patient cohort studies will 
be integrated with animal investigations that enable more accurate interpretation of observed 
host-microbiome traits.
It is a brave new world, where ecologists and data scientists are being integrated into clinical 
departments, but this paradigm shift is a necessary precondition to realize the potential of 
microbiome-informed and microbiome-based medicine. The societal need for improved 
medical interventions and preventive strategies is driving a sea-change in both the clinical 
and commercial world. The onus is on the basic and clinical translational research 
community to ensure that our experimental designs are robust and can deliver on the 
promises of this field. Just as important are the technical advances that must occur to ensure 
that we have the tools to derive the data to test our hypotheses. The microbial ecology 
community came together in 2015–2016 to support the proposal for a National Microbiome 
Initiative, which was in turn supported by the United States President’s Office of Science 
and Technology Policy82; one of the key outcomes of this effort was the identification of 
gaps in our technologies that would need to be filled to realize the full potential of 
microbiome science83. We have a long way to go, but with each new investigation we are 
moving closer to the realization of more effective diagnosis, treatment, and preventive 
modalities to improve human wellness and fight disease.
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Box 1:
How many microbial cells and genes colonize a human?
Although a frequently reported figure is that our microbes outnumber our own cells by 
10:1, this number stems from a 1972 article which uses a ‘back of the envelope 
calculation’ to arrive at this ratio84. A more prosaic figure was provided by Rosner85 of 
between 5 and 724 × 1012 human cells, and between 30 and 400 × 1012 bacterial cells. 
More recently, a refined estimate based on experimental observation and extrapolation 
actually arrives at a ratio of 1.3 bacterial cells for every one human cell1. However, these 
estimates don’t take into consideration the viruses and phage present in various body 
environments, which could equal bacterial estimates or more likely outnumber them by at 
least an order of magnitude86. Although these estimates reduce the extent to which 
microbial cells outnumber human cells, they do not reduce the estimates associated with 
the diversity of microbial life associated with the human body. Bacteria and other 
microbes including archaea, fungi, and arguably, viruses, are extremely diverse. A 
similarly rough estimate of 1000 bacterial species in the gut with 2000 genes per species 
yields an estimate of 2,000,000 genes, 100 times the figure of approximately 20,000 
human genes2. This agrees well with the actual size of microbial gene catalogues 
obtained by MetaHIT87 and the Human Microbiome Project13.
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Box 2:
The microbiome as novel biomarkers for disease
There is extensive evidence for many diseases that the microbiome can be used to explain 
a substantially greater percentage of the variance in the relevant phenotypes for a given 
condition within a population than can human genetic factors. For example, in individuals 
with Clostridium difficile infection (CDI), the aberrant stool microbiome looks nothing 
like a healthy stool but rather more like the microbiome of a completely different body 
site. Fecal microbiota transplant is able to cure C. diff infection and after transplantation 
the restoration of the stool microbiome to a community that matches that of the healthy 
state is both rapid and visible88. The C. diff infection has a much larger impact on the 
stool microbiome composition than does any human genetic variation observed to date, 
which may explain the high efficacy of stool transplant relative to standard antibiotic 
treatments for C. diff89.
Obesity provides an example in which human genetics has failed to explain the obesity 
epidemic, in contrast, the gut microbiome can classify individuals as lean or obese with 
over 90% accuracy within the context of a given case-control study90, although this result 
depends on using the correct methods91,92. Conversely the abundance of Christensenella 
within the human gut are negatively correlated with BMI, and can induce weight loss 
when experimentally fed to mice15.
Autism Spectrum Disorder has a complex presentation of symptoms, and is difficult to 
attribute entirely to host genetics, mainly due to the number of confounding influences 
and variables93. Yet the environmental interaction, and potentially the microbiome, plays 
a substantial role in shaping the etiology of the disease94,95. Animal models have been 
used to indicate the ability of bacterial metabolites in mediating autism-like behaviours96, 
and fecal microbiota transplant in humans has been associated with improvement in 
behavioral and gastrointestinal symptoms of autism 97. In further work, the link between 
host genetics, behavior and the gut microbiome has been partially elucidated, identifying 
a strong association between Lactobacillus and memory formation98.
A host of allergic and immune diseases has increased in frequency in parallel to the 
above metabolic and cognitive diseases. These include childhood-onset asthma, and 
allergies, including food and cutaneous allergies. Similarly, inflammatory bowel disease 
and type 1 diabetes has been increasing globally, which cannot be explained by 
differences in assessment practices. A growing body of evidence is linking these with 
altered microbiota compositions, especially loss of diversity, seen in Inflammatory Bowel 
Disease patients99,100 and children at risk for T1D101. One hypothesis is that this might 
be linked to a microbiome perturbation, in general, rather than the acquisition or loss of 
specific microbes that modify phenotype 102. Perturbation of microbiomes during early 
life might be particularly important because that is when immunity, metabolism, and 
cognition are under development.
A large Canadian study of infant stool samples (n=319) collected over the first 90 days of 
life, compared the early-life (first 90 days) faecal microbiota of infants who went on to 
develop allergic sensitization and wheezing at age two, to subjects who did not. The 
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depletion of certain bacterial taxa was characteristic of atopic children, and corresponded 
with reduced concentrations of faecal acetate and dysregulation of enterohepatic 
metabolites103, suggesting that the foundation for allergic disease development occurs in 
early life and is mediated at least in part by gut microbiome dysbiosis.
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Figure 1: 
The human microbiome is highly personalized. Understanding the relevance of the differing 
microbiota between individuals is confounded by the uniqueness of an individuals’ 
microbiome. The different colours in the pie charts represent different species.
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Figure 2: 
The dynamics of the human microbiome. The human microbiome has been shown to be 
highly dynamic. A) Taking a “representative” sample of a human microbiome at any given 
site is challenging because while the microbiome is known to settle after birth (green line), 
the composition can vary both over short term and long term timescales (orange line and 
blue line respectively). B) The effect of the rate of change of the varying species on the 
ability to take a representative sample as indicated by the black line is shown.
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Figure 3. 
Towards further understanding and developing therapies from microbiome data. The 
iterative cycle of analysis, interpretation and translational intervention that facilitate moving 
microbiome research out of correlative observation and into therapeutic treatments is shown.
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